A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS CD-19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS (CABA-201) IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Registry ID

CAB-201-001

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

CABALETTA BIO, INC.

Last update

2024-03-06

Conditions

• LUPUS ERYTHEMATOSUS

Related clinical trials

• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANIFROLUMAB IN ADULTS WITH CHRONIC AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS WHO ARE REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL THERAPY
• A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE 3, LONG-TERM EXTENSION STUDY TO EVALUATE CONTINUOUS SAFETY AND EFFICACY OF BIIB059 (LITIFILIMAB) IN ADULT PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYT
• A PHASE 3 PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SLE
• A MULTICENTER, RANDOMIZED, DOSE-BLIND, PHASE 3 LONG-TERM EXTENSION STUDY TO EVALUATEB CONTINUOUS SAFETY AND EFFICACY OF BIIB059 IN ADULT PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

View on source registry